<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509028</url>
  </required_header>
  <id_info>
    <org_study_id>D5254C00006</org_study_id>
    <nct_id>NCT00509028</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma</brief_title>
  <official_title>An Open-label, Multi-center, Long Term Study to Investigate the Safety and Efficacy of Budesonide Turbuhaler® Treatment for 48 Weeks (Following 6 Weeks Phase III Study) in Japanese Children With Bronchial Asthma Aged 5 Years to 15 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will include the patients who are Japanese children with bronchial asthma aged 5
      years to 15 years old and have completed the Phase III study (Study code: D5254C00769) at
      about 29 centres. To investigate the safety of budesonide Turbuhaler® with a daily dose of
      100 µg to 800 µg for 54 weeks treatment including the prior 6 weeks Phase III study (Study
      D5254C00769, NCT00504062) as compared with conventional therapy in Japanese children with
      bronchial asthma in need of inhaled glucocorticosteroid treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Adverse Events (AEs).</measure>
    <time_frame>54 weeks</time_frame>
    <description>AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Abnormal Clinical Laboratory Test Values.</measure>
    <time_frame>54 weeks</time_frame>
    <description>Analysis of haematological, clinical chemistry and urynalysis variables were performed.
Haematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count.
Clinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen.
Urinalysis variables: protein, glucose, urobilinogen, occult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Abnormal Plasma Cortisol Values.</measure>
    <time_frame>54 weeks</time_frame>
    <description>Cut-off value of cortisol is defined as 4 mcg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>Baseline and 54 weeks</time_frame>
    <description>Height, change from baseline calculated as (height at last visit - height at randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline and 54 weeks</time_frame>
    <description>Weight, change from baseline calculated as (weight at last visit - weight at randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal</measure>
    <time_frame>54 weeks</time_frame>
    <description>Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)</measure>
    <time_frame>Baseline and 54 weeks</time_frame>
    <description>Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4.
0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)</measure>
    <time_frame>Baseline and 54 weeks</time_frame>
    <description>Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization).
Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)</measure>
    <time_frame>Baseline and 54 weeks</time_frame>
    <description>Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)</measure>
    <time_frame>Baseline and 54 weeks</time_frame>
    <description>Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disturbance of Daily Activities</measure>
    <time_frame>Baseline and 54 weeks</time_frame>
    <description>Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization).
Frequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disturbance of Night-time Sleep</measure>
    <time_frame>Baseline and 54 weeks</time_frame>
    <description>Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization).
Frequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline</measure>
    <time_frame>54 weeks</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 * (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>BUD - Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONV - Conventional Asthma Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily</description>
    <arm_group_label>BUD - Budesonide</arm_group_label>
    <other_name>Pulmicort® Turbuhaler®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional Asthma Therapy</intervention_name>
    <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
    <arm_group_label>CONV - Conventional Asthma Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who complete preceding the Phase III study and provide a signed written
             informed consent by patient's legal representative at Visit 1 or 4 weeks prior to
             Visit 1 of the study. A signed written informed assent should also be obtained from
             the patients themselves as much as possible

          -  When the investigator will obtain the signed written informed consent of Phase III
             study (D5254C00769) from patient's legal representative, the investigator will also
             provide the information of this study

        Exclusion Criteria:

          -  Respiratory infections that, in the opinion of the investigator(s), may affect the
             efficacy evaluation e.g., lower airways infection such as pneumonia, infection with no
             available effective antimicrobial drugs or with deep seated mycosis

          -  Concurrent serious diseases of liver, kidney, heart or other complications which, in
             the opinion of the investigator, may either put the patient at risk because of
             participation in the study, or may influence the results of the study, or the
             patient's ability to participate in the study. Any clinically relevant abnormal
             findings in vital sign or physical examination at Visit 1 in this study, which in the
             opinion of the investigator may put the patient at risk because of his/her
             participation in the study.

          -  Pregnant or possible pregnancy or planning to become pregnant during the study period

          -  Other subjects who are considered inappropriate to participate in this study judged by
             the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars-Goran Carlsson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Lund</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takizawa</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <results_first_submitted>October 6, 2009</results_first_submitted>
  <results_first_submitted_qc>July 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2012</results_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Bronchial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>241 Japanese paediatric patients were enrolled into the study</recruitment_details>
      <pre_assignment_details>This was an open-label, multi-centre, long-term study in Japanese children with bronchial asthma aged 5 to 15 years, and conducted as an extension of the Phase III study D5254C00769.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Budesonide</title>
          <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
        </group>
        <group group_id="P2">
          <title>Conventional Therapy</title>
          <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Budesonide</title>
          <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
        </group>
        <group group_id="B2">
          <title>Conventional Therapy</title>
          <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="241"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9" spread="2.6"/>
                    <measurement group_id="B2" value="8.6" spread="2.3"/>
                    <measurement group_id="B3" value="8.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Adverse Events (AEs).</title>
        <description>AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.</description>
        <time_frame>54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events (AEs).</title>
          <description>AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Abnormal Clinical Laboratory Test Values.</title>
        <description>Analysis of haematological, clinical chemistry and urynalysis variables were performed.
Haematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count.
Clinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen.
Urinalysis variables: protein, glucose, urobilinogen, occult.</description>
        <time_frame>54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Abnormal Clinical Laboratory Test Values.</title>
          <description>Analysis of haematological, clinical chemistry and urynalysis variables were performed.
Haematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count.
Clinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen.
Urinalysis variables: protein, glucose, urobilinogen, occult.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator</title>
        <time_frame>54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Abnormal Plasma Cortisol Values.</title>
        <description>Cut-off value of cortisol is defined as 4 mcg/dL.</description>
        <time_frame>54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Abnormal Plasma Cortisol Values.</title>
          <description>Cut-off value of cortisol is defined as 4 mcg/dL.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Height</title>
        <description>Height, change from baseline calculated as (height at last visit - height at randomization)</description>
        <time_frame>Baseline and 54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Height</title>
          <description>Height, change from baseline calculated as (height at last visit - height at randomization)</description>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.34" spread="1.99"/>
                    <measurement group_id="O2" value="6.35" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <description>Weight, change from baseline calculated as (weight at last visit - weight at randomization)</description>
        <time_frame>Baseline and 54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <description>Weight, change from baseline calculated as (weight at last visit - weight at randomization)</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="2.77"/>
                    <measurement group_id="O2" value="4.39" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal</title>
        <description>Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).</description>
        <time_frame>54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal</title>
          <description>Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.54" spread="19.87"/>
                    <measurement group_id="O2" value="5.84" spread="17.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)</title>
        <description>Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4.
0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency</description>
        <time_frame>Baseline and 54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)</title>
          <description>Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4.
0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency</description>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.139" spread="0.334"/>
                    <measurement group_id="O2" value="-0.156" spread="0.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)</title>
        <description>Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization).
Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.</description>
        <time_frame>Baseline and 54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)</title>
          <description>Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization).
Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.</description>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.29"/>
                    <measurement group_id="O2" value="-0.147" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)</title>
        <description>Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)</description>
        <time_frame>Baseline and 54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)</title>
          <description>Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)</description>
          <units>Puffs per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.647"/>
                    <measurement group_id="O2" value="-0.242" spread="0.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)</title>
        <description>Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)</description>
        <time_frame>Baseline and 54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)</title>
          <description>Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)</description>
          <units>Puffs per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.415"/>
                    <measurement group_id="O2" value="-0.097" spread="0.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disturbance of Daily Activities</title>
        <description>Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization).
Frequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).</description>
        <time_frame>Baseline and 54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disturbance of Daily Activities</title>
          <description>Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization).
Frequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).</description>
          <units>Disturbances per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" spread="0.141"/>
                    <measurement group_id="O2" value="-0.017" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disturbance of Night-time Sleep</title>
        <description>Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization).
Frequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).</description>
        <time_frame>Baseline and 54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disturbance of Night-time Sleep</title>
          <description>Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization).
Frequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).</description>
          <units>Disturbances per night</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.029" spread="0.134"/>
                    <measurement group_id="O2" value="-0.042" spread="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline</title>
        <description>Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 * (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).</description>
        <time_frame>54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline</title>
          <description>Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 * (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="15.59"/>
                    <measurement group_id="O2" value="2.31" spread="16.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Budesonide</title>
          <description>Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily.</description>
        </group>
        <group group_id="E2">
          <title>Conventional Therapy</title>
          <description>According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenoviral conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dermatitis Atopic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Heat Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>AZTrial_Results_Posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

